Study of TQB3909 tablets for chronic lymphocytic leukemia or small lymphocytic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new pill (TQB3909) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to earlier treatments. It compares TQB3909 with the doctor's choice of standard treatment to see which works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with CLL or SLL that needs treatment and has not responded well or has stopped responding to prior therapies like chemo-immunotherapy or BTK inhibitors.
- You are generally able to care for yourself (ECOG score 0-2) and expected to live more than 3 months.
- Your major organs (like heart, liver, kidneys) are working well enough.
- If you have SLL, you must have at least one measurable tumor on a CT or MRI scan.
- You agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
This study tests an experimental pill (TQB3911) for people with chronic myeloid leukemia (CML) who have not responded well to or could not tolerate standard treatments. The goal is to find out if the drug is safe and what side effects it may cause.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This study tests two targeted oral medications, zanubrutinib and sonrotoclax, for people with CLL or SLL that has come back. The goal is to see if combining them can control the disease better and with fewer side effects than current options.
Hear when a new Small Lymphocytic Lymppho trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.